Nikko Asset Management Americas’s Nurix Therapeutics NRIX Stock Holding History

Nikko Asset Management Americas’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8M	Sell	983,462 -197,684	-17%	-$3.37M	0.31%	64
2026 Q1	$18.3M	Sell	1,181,146 -109,408	-8%	-$1.81M	0.26%	65
2025 Q4	$24.5M	Sell	1,290,554 -266,925	-17%	-$3.83M	0.28%	71
2025 Q3	$14.4M	Buy	1,557,479 +168,205	+12%	+$1.75M	0.14%	86
2025 Q2	$15.8M	Buy	1,389,274 +633,304	+84%	+$6.84M	0.16%	78
2025 Q1	$8.98M	Sell	755,970 -33,252	-4%	-$556K	0.12%	86
2024 Q4	$14.9M	Buy	789,222 +236,620	+43%	+$5.42M	0.16%	78
2024 Q3	$12.4M	Buy	+552,602	New	+$12.5M	0.14%	82

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nikko Asset Management Americas's NRIX Position: Q2 2026 in Review

Nikko Asset Management Americas reduced its Nurix Therapeutics (NRIX) stake by 17% in Q2 2026, selling an estimated $3.37M and leaving 983,462 shares worth $23.8M. The position accounts for 0.31% of the portfolio, ranked #64.

Nikko Asset Management Americas first reported a position in NRIX in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.5M in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Nikko Asset Management Americas held 983,462 shares of Nurix Therapeutics worth $23.8M as of Q2 2026.
Nikko Asset Management Americas sold 197,684 Nurix Therapeutics shares in Q2 2026, an estimated $3.37M.
Nurix Therapeutics made up 0.31% of Nikko Asset Management Americas's portfolio in Q2 2026, its #64 holding.
Nikko Asset Management Americas first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 8 quarters since.
Nikko Asset Management Americas's Nurix Therapeutics position peaked at $24.5M in Q4 2025.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.